ClinicalTrials.Veeva
Menu

Find clinical trials for Multiple Sclerosis (MS) in Madrid, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Multiple Sclerosis
Sclerosis
Chronic Progressive Multiple Sclerosis
Relapsing-Remitting Multiple Sclerosis
Autoimmune Diseases
Recurrence
Type 1F Charcot-Marie-Tooth disease

Multiple Sclerosis (MS) trials near Madrid, MD, ESP:

A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) (PORTAMENTO)

SC reference formulation in participants with either relapsing multiple sclerosis (RMS) or primary progressive multiple sc...

Enrolling
Multiple Sclerosis
Drug: Ocrelizumab Reference Formulation
Drug: Ocrelizumab Test Formulation

Phase 2

Roche
Roche

Madrid, Spain and 36 other locations

Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive Multiple Sclerosis (MAXIMS)

the efficacy and safety of oral masitinib versus placebo in the treatment of patients with primary progressive or secondary progressive multiple...

Active, not recruiting
Progressive Multiple Sclerosis
Drug: Placebo
Drug: Masitinib (4.5)

Phase 3

AB Science
AB Science

Madrid, Spain and 36 other locations

Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis

To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS...

Active, not recruiting
Multiple Sclerosis
Drug: Interferon beta-1a
Drug: Placebo capsule

Phase 3

Novartis
Novartis

Madrid, Spain and 72 other locations

A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS) (FUSION)

In this study, researchers will learn more about a study drug called BIIB091 in participants with MS who may be experiencing relapses. It is...

Active, not recruiting
Relapsing Forms of Multiple Sclerosis
Drug: BIIB091
Drug: DRF

Phase 2

Biogen
Biogen

Madrid, Spain and 78 other locations

A Study to Evaluate the Safety, Tolerability, and Efficacy of BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatment of Relapsing-Remitting Multiple Sclerosis

This study will evaluate the safety, tolerability, and descriptive efficacy of BIIB017 in pediatric participants with relapsing-remitting multiple...

Active, not recruiting
Multiple Sclerosis, Relapsing-Remitting
Drug: Interferon beta type 1a
Drug: BIIB017 (peginterferon beta-1a)

Phase 3

Biogen
Biogen

Madrid, Spain and 65 other locations

A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS) (FENerations1)

This open label, single arm study will evaluate the PK and PD effects of fenebrutinib in children and adolescents with RMS aged between 10 and \< 18...

Enrolling
Relapsing Multiple Sclerosis
Drug: Fenebrutinib

Phase 2

Roche
Roche

Madrid, Spain and 15 other locations

A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)

This study aims to examine the efficacy and safety of obexelimab in participants with relapsing multiple sclerosis...

Active, not recruiting
Relapsing Multiple Sclerosis
Drug: Placebo
Drug: Obexelimab

Phase 2

Zenas BioPharma

Madrid, Spain and 46 other locations

A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) (Operetta 2)

This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with...

Active, not recruiting
Relapsing-Remitting Multiple Sclerosis
Drug: Ocrelizumab
Drug: Fingolimod

Phase 3

Roche
Roche

Madrid, Spain and 102 other locations

Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)

YTB323 administration to 28 participants with non-active Progressive Multiple Sclerosis (PMS). The study design utilizes an ascendi...

Enrolling
Progressive Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Majadahonda, Madrid, Spain and 16 other locations

An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis

kinetics of YTB323 in approximately 28 participants with Relapsing Multiple Sclerosis (RMS) with breakthrough disease activity duri...

Enrolling
Relapsing Multiple Sclerosis
Biological: rapcabtagene autoleucel (YTB323)

Phase 1, Phase 2

Novartis
Novartis

Madrid, Spain and 16 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems